Research programme: lipocalins - Pieris Pharmaceuticals

Drug Profile

Research programme: lipocalins - Pieris Pharmaceuticals

Alternative Names: Anticalin®; Anticalins®; CardioClean; DigiCal; OncoCal I; Pieries-110; PRS-010; PRS-030; PRS-055; PRS-056; PRS-060; PRS-070; PRS-090; PRS-110; PRS-130; PRS-190

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator Pieris
  • Developer Allergan; Pieris; Pieris Pharmaceuticals; University of Melbourne; Zydus Cadila
  • Class Lipocalins
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Interleukin 23 inhibitors; Interleukin 4 receptor antagonists; Interleukin-17 inhibitors; Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma; Cancer
  • No development reported Autoimmune disorders; Eye disorders
  • Discontinued Cardiovascular disorders

Most Recent Events

  • 27 Feb 2017 Pieris plans a phase I trial for PRS 060 for the treatment of Asthma
  • 01 Jul 2015 No development reported - Preclinical for Autoimmune disorders in Germany (unspecified route)
  • 14 May 2015 Pieris and Stanford University agree to co-develop lipocalins in USA for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top